New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2013
10:00 EDTGALTGalectin Therapeutics rises 14.3%
Galectin Therapeutics is up 14.3%, or 33c, to $2.64
News For GALT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
17:05 EDTGALTEmpery Asset reports 5.53% passive stake in Galectin Therapeutics
Subscribe for More Information
November 20, 2015
08:57 EDTGALTGalectin Therapeutics 4.762M share Secondary priced at $2.06
Roth Capital acted as sole book running manager for the offering.
November 11, 2015
08:06 EDTGALTGalectin Therapeutics presents research on development of GR-MD-02
Galectin Therapeutics announces that preclinical research from a study led by Stefanie Linch, Ph.D. in the laboratory of tumor immunology expert William L. Redmond, Ph.D. of the Providence Cancer Center's Earle A. Chiles Research Institute was presented at the Society for Immunotherapy of Cancer's 30th Anniversary Annual Meeting. The meeting was held November 4-8 in National Harbor, Maryland. The studies presented were conducted by the Institute in collaboration with Galectin Therapeutics. The study found that GR-MD-02 boosts the frequency and persistence of antigen-specific T cells in non-tumor bearing mice. Additionally, GR-MD-02 in combination with anti-OX40, a monoclonal antibody in clinical development that activates the immune system, improved survival in mammary carcinoma models, and in a prostate cancer model. The combination also reduced lung metastases in the mammary carcinoma model. Within the tumor, an increase in the number of CD8 and CD4 tumor-infiltrating lymphocytes was observed. The combination treatment also reduced functional tumor vasculature in the model.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use